Anagliptin, which is only approved since 2012 in the Japanese market, seems to have serum lipid-lowering and anti-atherogenic actions as well, which makes it unique among the gliptins approved so far (101, 102)
Tirzepatide Injection $289/mo
Retatrutide is an investigational triple incretin receptor agonist acting on GLP-1, GIP, and glucagon receptors currently undergoing clinical trials for the treatment of obesity and type 2 diabetes
Even though some studies have shown that sucralose is safe to eat, recent research notes that consuming sucralose is associated with various adverse health effects including systemic inflammation, metabolic diseases, disruptions in gut microbiota, and morewith the study authors saying that sucraloses safety and long-term impact should be reconsidered
However, these medications also slow digestion and reduce appetiteleading to significant weight loss in many patients